FLASCO Spring Congress featuring Business of Oncology Summit 2026 – Orlando

More information soon.

Industry Digital Posters

Sustained long-term control of terminal complement activity with ravulizumab or danicopan add-on to ravulizumab in patients with paroxysmal nocturnal hemoglobinuria
Gaby Andonie, PharmD, BCIDP, Medical Science Liaison
Alexion Pharmaceuticals

Consensus Guidance on Early Identification and Management of Peripheral Neuropathy in Patients with UC Receiving Enfortumab Vedotin: A Delphi Study
Charlene Whittlesey, Genitourinary Medical Science Liaison
Astellas

Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: results from an ongoing phase I trial
Brian Elliott, Associate Director, Medical Science Liaison
Boehringer Ingelheim

Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG 1
Brian Elliott, Associate Director, Medical Science Liaison
Boehringer Ingelheim

6-year outcomes with first-line (1L) nivolumab plus ipilimumab plus chemotherapy (N+I+C) in patients with metastatic non-small cell lung cancer (mNSCLC) with and without brain metastases from CheckMate 9LA
Josean Vargas-Maisonet, PharmD, Executive Medical Science Liaison
Bristol Myers Squibb

Patient preference for subcutaneous (SC) vs intravenous (IV) nivolumab (NIVO) in participants with resected melanoma: primary endpoint analysis of a phase 2 open-label study (CA224-1044)
Ingrid Rivera, Medical Science Liaison, Melanoma, and Gastrointestinal Cancers
Bristol Myers Squibb

Primary results from ASCENT-03: a randomized phase 3 study of sacituzumab govitecan (SG) vs chemotherapy (Chemo) in patients (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are unable to receive PD-(L)1 inhibitors (PD-[L]1i)
Cyril Clybouw, Principal Medical Science Liaison
Gilead Sciences Inc.

Efficacy and durability of belantamab mafodotin plus pomalidomide and dexamethasone treatment from long-term follow-up of the phase 3 DREAMM-8 study
Yamile Coto De Pani, Medical Director, Oncology Clinical Development, Oncology R&D
GSK

Clinical outcomes associated with new or worsening anemia and thrombocytopenia in ruxolitinib-treated, JAK inhibitor–naive patients with myelofibrosis: post hoc analysis from the phase 3 SIMPLIFY-1 trial
Dedra Evans, Senior Medical Science Liaison, Hematology
GSK

Olomorasib and immunotherapy in stage II-III KRAS G12C-Mutant NSCLC after definitive therapy: SUNRAY-02 study rationale
Sal Bottiglieri, Associate Director, Medical Science Liaison – Oncology (GI/GU/Thoracic) Gulf Southeast
Lilly Oncology

Longer survival with tagraxofusp (TAG) versus venetoclax (VEN) in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a real-world analysis
John Katsetos, PA-C, Sr. Scientific Director
Menarini Stemline

Safety and efficacy of linvoseltamab (LINVO) combined with anti-CD38 monoclonal antibodies (mAbs) daratumumab (DARA) or isatuximab (ISA) in patients with relapsed/refractory multiple myeloma (RRMM): initial results from the multicohort, Phase 1b LINKER-MM2 trial
Ryan N. Bookout, Associate Director, Field Medical Affairs – Hematology
Regeneron Pharmaceuticals

Slide Decks

Fares-Recognizing Toxicities of ADCs Lung Cancer

Gayle, MRD in Myeloma- Dr. Gayle

Grajales-Cruz-BsAb and ADC tox AFG

Kerr D.Alan-FLASCO lymphoma BsAb and ADC toxicities

Kim, Richard-FLASCO MRD 2026

Moustafa, Muhamad-MRD in DLBCL

Mukherjee, Sarbajit-FLASCO 2026 debate_SM

Nguyen, Nina-FLASCO Myeloma MRD Debate 2026_V2

Zhang, Julia-MRD in DLBCL – still informational

Zuberi, Lara-ADCs FLASCO